CLVS share discount pricing won't last long

112 0 0
Big recovery moves when it hits the bottom trend line last two times, about to do the same a third time. Probably a coincidence, but both of the previous take downs were followed by some good news. It wouldn't be too surprising if someone out there knows something we don't and is trying to shake out weak hands to get cheap shares. Expecting this to be $90+ soon.

Rolling NDA submission for Rocilentinib will be completed by July/August and will serve as another positive catalyst. Although CLVS             management has said on the record that they are planning to bring their drugs to market on their own, I still believe they are just playing hard to get for now to minimize rampant speculation and liability of forward-looking statements. Current market cap sits around $2.8B with peak sales potential of about $2B/year for Rocilentinib. This doesn't even fully take into account Rucaparib that will likely file its NDA in 1Q16 and will compete with already approved Lynparza by AstraZeneca ( AZN             ) that has $3B/yr sales potential. A buyout offer of at least $6-10B will be difficult to refuse, and even without the offer, the company deserves a valuation of $160+ once Rocilentinib is approved.
EN English
EN English (UK)
EN English (IN)
DE Deutsch
FR Français
ES Español
IT Italiano
PL Polski
SV Svenska
TR Türkçe
RU Русский
PT Português
ID Bahasa Indonesia
MS Bahasa Melayu
TH ภาษาไทย
VI Tiếng Việt
JA 日本語
KO 한국어
ZH 简体中文
ZH 繁體中文
AR العربية
Home Stock Screener Forex Signal Finder Cryptocurrency Signal Finder Economic Calendar How It Works Chart Features House Rules Moderators Website & Broker Solutions Widgets Stock Charting Library Feature Request Blog & News FAQ Help & Wiki Twitter
Profile Profile Settings Account and Billing My Support Tickets Contact Support Ideas Published Followers Following Private Messages Chat Sign Out